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In addition to target efﬁcacy, drug safety is a major requirement during the drug discovery process and is
inﬂuenced by target speciﬁcity. Therefore, it is imperative that every new drug candidate be proﬁled
against various liability panels that include protein kinases. Here, an effective methodology to streamline
kinase inhibitor proﬁling is described. An accessible standardized proﬁling system for 112 protein kinases
covering all branches of the kinome was developed. This approach consists of creating different sets of
kinases and their corresponding substrates in multi-tube strips. The kinase stocks are pre-standardized
for optimal kinase activity and used for inhibitor proﬁling using a bioluminescent ADP detection assay.
We show that these strips can routinely generate inhibitor selectivity proﬁles for small or broad kinase
family panels. Lipid kinases were also assembled in strip format and proﬁled together with protein ki-
nases. We identiﬁed two speciﬁc PI3K inhibitors that have off-target effects on CK2 that were not re-
ported before and would have been missed if compounds were not proﬁled against lipid and protein
kinases simultaneously. To validate the accuracy of the data generated by this method, we conﬁrmed that
the inhibition potencies observed are consistent with published values produced by more complex
technologies such as radioactivity assays.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Kinases, one of the largest enzyme families in the cell, represent
important biological intersections in signaling pathways [1]. By
phosphorylating a diverse array of substrates of various chemical
natures (e.g., proteins, lipids, sugars), kinases catalyze the largest
number of post-translational protein modiﬁcations (PTMs); it has
been reported that more than 75% of PTMs are phosphorylations
[2]. Kinases orchestrate a multitude of biological processes such as
cellular growth, division, and differentiation [1e3]. As a corollary,
disruption of these biological processes due to abnormal kinase
activity can have a deleterious effect on the cell, leading to serious
diseases such as cancer, inﬂammation, and diabetes. For nearly two
decades, kinases have been one of the most targeted enzymeiﬁcation; FDA, U.S. Food and
MSO, dimethyl sulfoxide; TK,
APK, GSK3, and CLK families;
se-like families; HTS, high-
. Zegzouti).
19, USA.
Inc. This is an open access article ugroups in drug discovery research [4,5]; some 30 kinase-based
drugs have been approved by the U.S. Food and Drug Administra-
tion (FDA), and many are currently undergoing development or in
clinical trials [5,6].
In 2001, Gleevec (against ABL kinase) was the ﬁrst kinase in-
hibitor approved to treat a cancer, chronic myelogenous leukemia
[7]. It became a promising proof of concept that drugs could also be
developed against other diseases involving dysregulated kinase
activity. Althoughmany kinases were validated as drug targets for a
variety of diseases, the majority of approved kinase inhibitor drugs
up to now are for treating different types of cancer; only three have
been approved for non-oncological diseases. For example, myelo-
ﬁbrosis, rheumatoid arthritis, and idiopathic pulmonary ﬁbrosis are
treated with the kinase inhibitors ruxolitinib (JAK1/2), tofacitinib
(JAK3), and nintedanib (VEGFR, FGFR, and PDGFR), respectively
[8e10]. If success in developing kinase inhibitor drugs has been
limited, one reason is that the majority of inhibitors bind to the
evolutionary conserved ATP binding pocket common to all kinases.
Therefore, it is challenging to identify highly selective inhibitors
that will not inhibit off-target kinases and affect other crucial
signaling pathways leading to side effects when used as a therapy.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
J. Hennek et al. / Analytical Biochemistry 495 (2016) 9e2010Reduced selectivity may be a lesser concern when treating cancer
given that some off-target effects may be tolerated for the greater
beneﬁt of the therapy [11]. However for nonlethal maladies, high
target selectivity is critical for avoiding side effects due to drug
toxicities that could outweigh the therapeutic beneﬁts of the drug
and cannot be managed. This could explain why the majority of the
drugs approved are for the treatment of cancer. Many pharma-
ceutical companies endeavor to develop drugs that have the right
balance between potency and selectivity for cancer and for other
ailments [5] such as chronic inﬂammatory and autoimmune dis-
eases [12], hypertension, and Parkinson's disease [13].
Many drug discovery programs are devoted to the identiﬁcation
of kinase inhibitors with an adequate balance between potency and
selectivity. To achieve this balance, new drug entities need to be
proﬁled against various liability panels including protein kinases.
Proﬁling a compound against a broad panel of kinases provides a
better understanding of its mode of action andmay reveal potential
toxicities [14,15]. Moreover, deﬁning speciﬁcity of inhibitors toward
a particular kinase or kinase group has proved to be useful to the
research community in general and to the cell-signaling commu-
nity in particular [16,17].
Several kinase detection assays have been developed for kin-
aseesmall molecule interactions in low-to high-throughput set-
tings [18e21]. These technologies are used either to measure the
effect of the small molecule on the catalytic activity of the kinase or
to assess the binding afﬁnity to the ATP binding pocket. Although
these assays are classically used for a small number of kinases at a
time in a screening or characterization mode, they are mostly
deployed for proﬁling in a fee-for-service model by service pro-
viders [22e27]. Some offer large kinase panel proﬁling using
activity-based radiometric assays [23,26]. Others use phage
display-based binding assays because they provide large kinase
panel proﬁling service [24,25]. Other technologies, such as mobility
shift kinase assays, were also adopted by others to provide large
kinase panel proﬁling service. This fee-for-service model is attrac-
tive given the difﬁculty of setting up large proﬁling kinase panels.
However, although cost, time, and conﬁdentiality factors may
prohibit the use of a service provider, the alternative of creating and
maintaining kinase panels in-house may also be cost prohibitive
and cumbersome. It would involve rigorously optimizing each
enzyme across the panel and keeping a large number of kinase
stocks in a perfect stable condition to be used each time a com-
pound selectivity proﬁle is needed [28e30].
In this article, we describe the development of a pre-conﬁgured
and standardized kinase proﬁling system that can be implemented
as a cost-effective in-house approach. The system is based on
luminescent ADP detection by the ADP-Glo kinase assay, a universal
platform that has been validated with a large number of kinases for
drug discovery, enzyme characterization, and inhibitor mode of
action studies [19,31e36]. The kinase proﬁling systems are a set of
kinases presented in one-time-use multi-tube strips containing
eight enzymes each with their corresponding substrate strips and
are standardized for optimal kinase activity. The strip system pro-
vides ﬂexible kinase inhibitor proﬁling because each strip can be
used to proﬁle compounds at a single dose or to create a dose range
against eight kinases at once. We created a proﬁling panel con-
taining 112 kinases belonging to all kinase branches of the kinome
[1]. We show that this kinase proﬁling strip approach can routinely
generate selectivity proﬁles against small or large kinase panels and
can identify compound promiscuity across the kinome.
Finally, because chemical compounds speciﬁc for one class of
kinases such us lipid kinases can potentially have off-target effects
and inhibit kinases in other groups of the kinome, we also assem-
bled four class I PI3 kinases in strip format and tested them in an
inhibitor proﬁling experiment. When these were used with proteinkinases in the same proﬁling experiments, unknown off-target ef-
fects of speciﬁc PI3 kinase inhibitors were identiﬁed, emphasizing
the importance of proﬁling lipid and protein kinases
simultaneously.
Materials and methods
Materials
Kinases, substrates, and cofactors were obtained from Signal-
Chem (Richmond, BC, Canada), except PKA, PKC, DNA-PK, PI3 ki-
nases a, b, g, and d, neurogranin, kemptide, and DNA-PK peptide,
whichwere obtained fromPromega (Madison,WI, USA). Table S1 in
the Online Supplementary Material provides a list of all the kinases,
substrates, and cofactors used in this study. SB203580was obtained
from Promega. Geﬁtinib, roscovitine, dasatinib, tofacitinib, toza-
sertib, LY294002, AZD6482, AS252424, and AS605240 were pur-
chased from LC Laboratories (Woburn, MA, USA). The ADP-Glo
kinase assay was obtained from Promega. Low-volume, 384-well,
white round-bottom untreated polystyrene microplates and half-
area 96-well white untreated microplates were obtained from
Corning (Corning, NY, USA). Bovine serum albumin (BSA; blot-
qualiﬁed BSA, cat. no. 3841) was obtained from Promega.
Kinase assay conditions
All kinase reactions were performed in kinase reaction buffer
(40 mM Tris [pH 7.5], 20 mM MgCl2, 0.1 mg/ml BSA, and 50 mM
dithiothreitol) supplemented with 10 mMATP and various cofactors
(Table S1). All kinase reactions were performed in a 5-ml volume in
384-well plates and were incubated for 1 h at room temperature
(22e25 C).
Kinase and substrate strip assembly
All of the kinases were serially diluted starting from 200 ng per
reaction with their substrate and cofactors (concentrations indi-
cated in Table S1). Once optimal kinase concentration was deﬁned,
the kinases were diluted in a kinase storage buffer to make a 50
concentrated stock and the substrates/cofactors were diluted to
make a 3.3 concentrated stock. These kinases and substrates were
grouped by kinase family, assembled inmulti-tube PCR strips (eight
kinases or eight substrates per strip), and stored at 80 C as one-
time-use aliquots. The kinase and substrate aliquots are 5 and 45 ml
per tube, respectively.
Kinase proﬁling system general protocol
Each kinase stock in the kinase strip was diluted with 95 ml of
2.5 kinase reaction buffer, and each substrate/cofactor stock in
the substrate strip was diluted with 15 ml of 100 mM ATP. Both
kinase and substrate/cofactor concentrations are now 2.5. As
described in Fig. 3 (see Results and Discussion), 2 ml of the kinase
working stocks and 2 ml of the ATP/substrate working stocks were
dispensed in the 384-well plate wells along with 1 ml of buffer,
compound, or 5% dimethyl sulfoxide (DMSO; vehicle) in a buffer.
The reactions were incubated for 1 h at room temperature. To
detect the activity of each kinase, the ADP-Glo kinase assay was
used according to the manufacturer's protocol and previously
published method [19]. Brieﬂy, to the 5-ml kinase reactions, 5 ml of
ADP-Glo reagent was added to stop the kinase reaction and
deplete any ATP remaining. The mixture was incubated for 40 min
at room temperature. Then, 10 ml of kinase detection reagent was
added and the mixture was incubated for an additional 30 min to
convert the kinase-produced ADP to ATP and then to light using
Fig.1. Kinase targets selected for the kinase proﬁling panel. The kinases are presented on a kinome dendogram based on their relationships in terms of sequence homology and for
visualization of the groups to which they belong. Each kinase group is represented with a different color (e.g., red for TK [tyrosine kinase] group) except that the “Other” group
kinases spread all over the kinome have a gray color. The bottom panels represent how the 112 kinases are organized in the 14 eight-strip tubes.
J. Hennek et al. / Analytical Biochemistry 495 (2016) 9e20 11luciferase/luciferin reaction. The light generated was measured
using a luminometer (GloMax Discover, Promega). The lumines-
cent signal generated is proportional to the ADP concentration
present, and it is correlated with the amount of kinase activity.
More details about the ADP-Glo assay protocol and its applications
were described previously [19].
Kinase inhibitor proﬁling
Six compounds were used to validate the proﬁling system's
ability to accurately create kinase inhibition proﬁles. The systems
were tested with inhibitors as a single-dose inhibition or in dos-
eeresponse mode to calculate percentage activity remaining after
incubating with one inhibitor dose or to calculate IC50 values for
eight enzymes at a time. Step-by-step proﬁling methods described
previously, and illustrated in Figs. S1 and S2 in the Supplementary
Material, were followed [37]. Brieﬂy, kinase assays were assembled
using 1 ml of 5 concentrated compound, 2 ml of kinase working
stock, and 2 ml of the corresponding ATP/substrate working stock in
a 384-well plate. The volumes aliquoted in the kinase proﬁling
strips are sufﬁcient for either one 10-point inhibitor dose response
or up to 10 compounds tested at a single dose. In every experiment,
no-enzyme and no-compound control reactions were included to
represent background luminescence (0% activity) and non-
inhibited kinase activity (100% activity), respectively. The re-
ported percentage kinase activity was calculated by subtracting theaverage no-enzyme control luminescence from all kinase-
containing reactions with or without compound and then con-
verting these net luminescence values to percentage activity based
on the no-compound control reactions representing 100% kinase
activity.
Results and discussion
To proﬁle a small molecule kinase inhibitor using an activity-
based kinase assay, different kinases are simultaneously assayed
in the presence and absence of the compound to be proﬁled. First,
an assay that is compatible with all of the kinases to be proﬁled is
selected. Second, prior to proﬁling, a titration of each enzyme is
used to select an appropriate amount to be used in the proﬁling
reactions. This amount of kinase should be as low as possible, in the
linear range of the enzyme activity and the assay, and should
produce a reasonable assay window (e.g., signal-to-background
ratio 10). This can reasonably managed with a small number of
kinases [29]. However, for large kinase panels or for repetitive
routine proﬁling, the logistics of maintaining enzyme stocks and
assay optimization become cost and labor intensive [28,30].
Therefore, we standardized the kinases for activity and created
one-time-use kinase and substrate stocks that can be stored in the
freezer with stable activity over time. The amounts chosen for each
kinase produce similar signal-to-background ratios across the
panel to create meaningful inhibitor potency comparisons. In
Fig.2. Standardizing kinase activities. Kinases were titrated eight at a time in 384-well plates using a 5-ml reaction volume, and their activities were analyzed using ADP-Glo assay as
described in Materials and Methods. The dashed insets represent the linear area of each kinase curve where the amount selected for each enzyme produces approximately 10e30%
ATP to ADP conversion with at least a signal-to-background ratio of 10 at 10 mM ATP. Curve ﬁtting was performed using a sigmoidal doseeresponse (variable slope) equation in
GraphPad Prism software. An ATP-to-ADP conversion curve in the 10 mM total nucleotide concentration was performed at the same time to correlate the percentage ADP produced
to each RLU (relative light units) value as described previously [19]. Luminescence values represent the averages of two replicates.
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with a small number of dispensing steps.Kinase selections and grouping
To create a meaningful kinase proﬁling panel, at least eight
representative kinases from each branch of the kinome were
selected. This provided at least one multi-tube strip containing
eight kinases from each subfamily (Fig. 1). The 112 kinases depicted
in Fig. 1 and grouped in 14 strips constitute a panel that covers the
human kinome in a representative fashion and contains the ma-
jority of drug targets identiﬁed to date. In addition, the kinases in
each branch of the kinome were chosen based on published panels
used for proﬁling during the last decade. The kinases selected have
been either commonly proﬁled in the literature or described in
different kinase drug discovery programs [5,28,38]. We includedkinase targets of the majority of FDA-approved kinase inhibitors [6]
that may serve as inhibition controls (Table 1).Standardizing kinase activities
Available recombinant kinases have a wide range of speciﬁc
activities, such that different volumes need to be dispensed from
each kinase stock to generate similar activities across a set. To
facilitate this process, we chose an amount of each enzyme that
converts approximately 10e30% ATP to ADP and produces a signal-
to-background ratio of at least 10 at 10 mM ATP. Based on this
amount of kinase, stock solutions were created in equal volumes so
that after a standardized dilution step, 2 ml of each kinase could be
used for each reaction.
The selected enzymes were titrated, eight at once starting
from 200 ng per reaction, using assay conditions that we
developed previously to create 174 kinase enzyme systems
Fig.3. Kinase proﬁling systems principle. Kinase stocks (50) were diluted directly in
the strip tubes with 2.5 kinase buffer, and substrates/cofactor stocks (3.3) were
diluted with 100 mM ATP solution to create working stocks (2.5). Kinase reactions
were performed using 1 ml of compound or vehicle control, 2 ml of kinase working
stock, and 2 ml of ATP/substrate working stock. After a 1-h incubation at room tem-
perature (22e25 C), kinase activity was quantiﬁed using the ADP-Glo kinase assay.
The luminescent signal generated is proportional to ADP concentration and is corre-
lated with kinase activity.
Table 1
FDA-approved small molecule drugs and their kinase targets present in the proﬁling sys
Drug Year approved Known target(s)a,b
Afatinib 2013 EGFR
Axitinib 2012 VEGFR1/2/3 (FLT1
Bosutinib 2012 ABL, SRC, LYN, HC
Cabozantinib 2012 RET, MET, VEGFR1
Ceritinib 2014 ALK, IGF1R, InsR,
Crizotinib 2011 ALK, c-MET, ROS
Dasatinib 2006 ABL, SRC, LCK, FYN
Dabrafenib 2013 B-RAF
Erlotinib 2004 EGFR
Geﬁtinib 2003 EGFR
Ibrutinib 2013 BTK
Idelalisib 2014 PI3Kd
Imatinib 2001 ABL, PDGFR, KIT
Lapatinib 2007 EGFR; HER2
Lenvatinib 2015 VEGFR, FGFR, RET
Nilotinib 2007 ABL, PDGFR
Nintedanib 2014 VEGFR, FGFR, PDG
Palbociclib 2015 CDK4/6
Pazopanib 2009 VEGFR, FGFR1/3, F
Ponatinib 2012 ABL and ABL T315
Regorafenib 2012 VEGFR, ABL, B-RA
Ruxolitinib 2011 JAK1/2
Sorafenib 2005 RAF, KIT, FLT3, RET
Sunitinib 2006 PDGFR, VEGFR, KI
Tofacitinib 2012 JAK3
Trametinib 2013 MEK1/2
Vandetanib 2011 EGFR, VEGFR, RET
Vemurafenib 2011 A/B/C-Raf, B-Raf (V
a The targets shown here are primary and secondary for each drug.
b The targets included in the proﬁling systems are shown in bold.
J. Hennek et al. / Analytical Biochemistry 495 (2016) 9e20 13(http://www.promega.com/kinase). Fig. 2 shows the titration
of eight kinases from the TK family and indicates the optimal
curve segments. As an example, the amount chosen from this
segment of the EGFR curve is represented in bold in Table 2 (e.g.,
12.5 ng/5 ml reaction). Because the kinases are sensitive to freeze/
thaw cycles and can lose activity when stored at low concen-
trations, a 50 concentrated stock of the amount identiﬁed by
titration was prepared in a storage buffer containing BSA and
glycerol. For the EGFR example, the 50 stock is 125 ng/ml, which
is aliquoted to 5 ml per strip tube and used one time to create
multiple proﬁling reactions. The volumes aliquoted in the kinase
proﬁling strips (5 ml) are sufﬁcient for either one 10-point in-
hibitor dose response or up to 10 compounds tested at a
single dose, and it is a one-time-use aliquot. It should be noted
that dispensing less than 5 ml of kinase stock in the kinase
proﬁling strips could decrease accuracy and reproducibility of
the technique. Thus, a drawback of one-time use of the kinase
strip could be that if fewer than 10 compounds are to be tested at
once in a single-dose experiment, the remaining reconstituted
kinase working solution cannot be refrozen and would go to
waste.
The substrate and cofactor concentrations are based on assays
developed previously and can be stored in amore diluted state than
the kinases. The substrate and cofactor mixtures were shown to be
stable in 80 C storage (data not shown). Therefore, we mixed the
substrate peptides or proteins and any needed cofactors such as
MnCl2, AMP, and lipids to make 3.3 concentrated stocks (see
Table S1 in Supplementary Material) and dispensed 45 ml per strip
tube. Each eight-kinase strip was paired with its corresponding
substrate/cofactor strip and stored at 80 C.
For ease of use, the proﬁling protocol was also standardized
(see Fig. 3 below) so that only one dilution each is required for the
kinase and the substrate stocks to create working solutions. Each
kinase and substrate stock is diluted with the same volume oftem panel described here.
Proﬁling family strip(s)
TK-1
) TK-4
K TK-2
/2/3, AXL, KIT, TRKB, FLT3, TIE2 TK-4, TK-3
ROS1 TK-1
TK-4
, PDGFRb, YES, KIT, EPHA2 TK-2, TK-1
N/A
TK-1
TK-1
TK-2
PI3K small panel
TK-2, TK-1
TK-1
, PDGFR, KIT TK-4, TK-1
TK-2, TK-1
FR TK-4, TK-1
CMGC-2
MS, PDGFR, KIT, LCK, ITK TK-4, TK-1, TK-2, TK-3
I, VEGFR, PDGFR, FGFR, SRC, KIT, RET TK-2, TK-4, TK1
F, KIT, PDGFR, RET, FGFR1/2, TIE2 TK-4, TK-2, TK-1
N/A
, VEGFR, PDGFR TK-4, TK-1
T, FLT3, CSF-1R, RET TK-1, TK-4
TK-3
N/A
, BRK, TIE2, EPHA, SRC family TK-1, TK-4, TK-2, TK-3
600E) N/A
Table 2
EGFR titration to deﬁne 50 concentration for proﬁling system development.
EGFR (ng)a: 200 100 50 25 12.5 6.3 3.1 1.6 0.8 0
RLU 56555 46326 36021 28000 13879 5887 2506 1072 568 158
S/B 358 293 228 117 88 37 16 7 4 1
% ADP 88 73 58 46 22 9 4 2 1 0
Note. RLU, relative light units; S/B, signal-to-background ratio.
a The optimal amount chosen for EGFR from the curve is represented in bold.
J. Hennek et al. / Analytical Biochemistry 495 (2016) 9e2014buffer or ATP. The working solutions become 2.5 concentrated
and are ready to be added to the kinase reaction. Because the
kinases were standardized for activity in 5-ml reactions, identical
volumes of both kinase and substrate working solutions (2 ml
each) are added across the plate to create a 1 reaction concen-
tration after 1 ml of buffer, compound, or vehicle (e.g., DMSO) is
added to the well. The incubation time was also standardized to
1 h to allow all of the kinases to generate similar percentage ATP
conversion.
To test the consistency of our approach, multiple 50 and 3.3
stocks of kinase and substrate strips, respectively, were made, and
their performances were compared with each other andwith initial
pilot stocks following the same protocol. Fig. 4 shows a comparison
between the performances of two stocks for eight kinases from the
CMGC family strip in terms of luminescence signal and signal-to-
background ratio. It shows that the stocks made and frozen over
time generated similar data in the previously speciﬁed activity
range. Multiple additional stocks that were generated showed
consistent performance and were stable for at least 9 months to 1
year at 80 C (data not shown). This demonstrates the validity of
this approach for developing proﬁling reagents in a large stock to be
aliquoted and used routinely.Validating kinase proﬁling systems with known inhibitors
We showed that consistent kinase activity measurement from
the kinase proﬁling systems can be obtained. To validate the utility
of our system for inhibitor proﬁling, we created single-dose and
doseeresponse inhibition proﬁles following the protocol described
in Fig. 3 and in Figs. S1 and S2 of the Supplementary Material. For
single-dose inhibition, four strips of eight kinases were used with
ﬁve known small molecule kinase inhibitors, either approved drugs
or research compounds. A single-dose proﬁling protocol described
in Fig. S1 was used, and we generated data representing percentageFig.4. Reproducibility of the kinase strip approach. Two independently made kinase
stock batches (50) of eight kinases from the CMGC group were created according to
the described protocol and stored at 80 C. The activities of both kinase sets were
tested using the strip protocol and compared. Luminescence (relative light units, RLU)
and signal-to-background (S/B) ratios shown are averages of replicates of both
measurements.of activity remaining in the presence of the compounds. The data
presented in Fig. 5 are consistent with previously published liter-
ature. The kinase proﬁling systems allowed the accurate detection
of different types of inhibition: (i) speciﬁc kinase inhibitors such as
tofacitinib, which is a potent and selective JAK3 inhibitor approved
for rheumatoid arthritis [9]; (ii) family selective inhibitors such as
geﬁtinib, which targets EGFR and HER2 in the family of ErbB ki-
nases [39], or dasatinib, whose main targets are ABL kinase and the
SRC family, along with several other tyrosine kinases, but not ErbB
family kinases such as EGFR and HER2 [40]. Moreover, the proﬁling
systems also distinguished inhibition nuances between selective
and potent kinase subfamily inhibitors such as dasatinib and less
potent but very selective subfamily inhibitors such as roscovitine.
Roscovitine is very selective for a number of cyclin-dependent ki-
nases (CDKs) but with less potency than the tyrosine kinase in-
hibitors described above [41]. As a control for our validation
experiment, the p38 MAPK speciﬁc inhibitor SB203580 [42,43] was
used and no inhibition was observed with the non-target kinases
used.
To validate the proﬁling system for doseeresponse inhibition,
the p38 MAPK family selective inhibitor SB203580 was used to
identify the IC50 rank order among 16 different CMGC family
kinases and more speciﬁcally in the p38 kinase subfamily. A
doseeresponse proﬁling protocol described in Fig. S2 was
applied here to generate IC50 data for each kinase that are
consistent with published literature [42] (Fig. 6A). SB203580 was
more potent against the target kinases p38a (IC50: 16 nM) and
p38b (IC50: 114 nM) than the other p38 kinases. Other members
of the CMGC family were either not inhibited (p38g, d, ERK2,
and CDKs) or weakly inhibited (JNK1, JNK3, and GSK3b IC50
values ¼ 3.3, 0.5, and 1.5 mM, respectively). These results validate
the robustness and practicality of our kinase proﬁling
strip concept in accurately identifying kinase inhibitors and
potencies.
Kinase inhibitor proﬁling for 112 kinases
The proﬁling strip approach proved to be useful for quick kinase
inhibitor proﬁling for small kinase panels. To validate these
proﬁling systems with a larger kinase panel, all 112 kinases in the
14 strips were used in one experimental setup. We adopted two
strips per 384-well plate for a total of seven plates and followed the
protocol for doseeresponse inhibitor proﬁling (Fig. S2). The
approach was simple enough for all solution dispensing to be done
manually. Seven replicate plates containing compound serial di-
lutions were created by dispensing 1 ml of pre-prepared SB203580
serial dilution stocks. Next, using two different kinase strips per
plate, kinase and substrate stock solutions were dispensed and the
plates were incubated before kinase activities were detected using
the bioluminescent ADP detection assay. To simplify data analysis
when large data sets are generated, worksheets (SMART protocols
at http://www.promega.com/resources/tools/) were created in
Microsoft Excel for calculating IC50 values according to a published
method [44]. To easily visualize the SB203580 inhibition proﬁle of
the 112-kinase panel, we created a bubble plot on the kinome
Fig.5. Validation of the strip approach for single-dose inhibitor proﬁle creation. A total
of 32 kinases from four different kinase strips were proﬁled against ﬁve kinase in-
hibitors (1 mM) at once using the single-dose inhibition protocol described in Fig. S1 of
the supplementary material. One 384-well plate column was used for each compound/
kinase strip pair reaction, one column was used for no-enzyme controls (0% kinase
activity), and one column was used for no-compound controls (100% kinase activity).
The percentages of activity remaining for kinase/compound pairs are shown and
represent the averages of two replicates. Data were collected using the single-dose
SMART protocol (http://www.promega.com/resources/tools/), which calculates the
percentage kinase activity by subtracting the no-enzyme control luminescence from all
kinase-containing reactions and then converting the net luminescence values to per-
centage activity based on the no-compound control reactions.
J. Hennek et al. / Analytical Biochemistry 495 (2016) 9e20 15image where bubbles represent IC50 values for all of the kinases
with size in proportion to potency (Fig. 6B). As predicted, the data in
Fig. 6B and Table 3 show that SB203580 is a potent and selective
inhibitor for both p38a and p38b. We were able to identify an off-
target kinase RIPK2 from a different kinome branch (TKL). RIPK2
was potently inhibited with an IC50 of 46 nM, which is closer to
p38a (IC50 ¼ 16 nM) than the other inhibited CMGC kinases such as
p38b and JNK3 (Fig. 6A and B and Table 3). RIPK2 was conﬁrmed to
be inhibited by SB203580 with a similar IC50 in a separate dos-
eeresponse experiment (data not shown), and this has also been
reported in the literature [45].For a quick assessment of the overall selectivity of a small
number of compounds identiﬁed during compound library
screening, it is useful to perform a single-dose inhibitor proﬁling.
To validate our approach for this purpose with a large kinase panel
in a single-dose proﬁling, 112 kinases were used in one experi-
mental setup with six compounds. We adopted three strips per
each 384-well plate for a total of 5 plates. The remaining kinase
activity for the 112 kinases in response to 1-mM inhibitor treat-
ments is presented as a heat map in Fig. 7 (right panel). As shown
previously, all of the speciﬁc and family inhibitions were
conﬁrmed. In addition, off-target activity of SB203580 on RIPK2
was conﬁrmed. Interestingly, RIPK2 was also inhibited by geﬁtinib
and dasatinib, which are tyrosine kinase family inhibitors. RIPK2
inhibition by these two inhibitors has also been reported in the
literature [23,45].
Many useful features of a convenient proﬁling approach have
been described here, showing that once proﬁling strips are made
and stored, compound selectivity assessments can be routinely
performed. This approach saves time, and because of its ﬂexibility it
can be used in various stages of kinase drug discovery. For example,
numerous hits from high-throughput screening (HTS) can be tested
simultaneously for selectivity in single-dose mode, or a few lead
compounds can be assessed for their potency in doseeresponse
mode across a large kinase panel. Although 112 kinases constitute
good coverage of the kinome and provide a general view of in-
hibitor selectivity, one shortcoming for the selected panel is that
the inhibition of some of the kinases not represented might be
missed.
Comparison of bioluminescent and radioactive kinase inhibitor
proﬁling
Radioactivity-based methods are considered the “gold stan-
dard” for many detection assays. However, additional assay for-
mats such as ﬂuorescence, luminescence, and absorbance have
been developed. When used for kinase activity detection, these
systems have some advantages such as ease of use, safety, and
homogeneous formats making them HTS friendly. But some
nonradioactive approaches have drawbacks such us high false
positive rates due to compound ﬂuorescence or absorbance, low
sensitivity, and requirements for modiﬁed substrates or different
antibodies for each assay [46]. Previously, we and others have
shown that bioluminescent ADP detection-based kinase assays
are similar to radioactive assays in sensitivity and IC50 de-
terminations [19,47]. We needed to validate the data generated
by the kinase proﬁling strips approach by comparing the inhi-
bition values obtained with previously published proﬁling data.
Several approaches were used for generating large biochemical-
based kinase proﬁling maps, measuring either the binding of
the small molecule to the kinases [24,48e50] or the inhibition of
kinase catalytic activity [23,26,27]. Here, we chose to compare
proﬁling strip data with a radioactive method because both as-
says are based on biochemical kinase activity detection. A com-
mon radiometric approach is based on ﬁlter binding where the
kinase reaction is performed in the presence of [g-32P]ATP or
[g-33P]ATP, followed by binding of the radioactive product to
ﬁlters. This technique requires washing to eliminate unbound
radioactive material before quantiﬁcation. Because of the
washing steps and safety concerns associated with radioisotope
handling, these technologies are not homogeneous and are un-
attractive to many researchers for large-scale kinase screening or
proﬁling. However, corporations such as Reaction Biology and
EMD Millipore do offer large-scale kinase proﬁling using radio-
metric assays as a fee for service. Anastassiadis and coworkers
described one of the largest proﬁling data sets using the
Fig.6. Validation of the strip approach for doseeresponse inhibitor proﬁle creation. (A) The p38 kinase inhibitor SB203580 was tested on two CMGC kinase strips in 10-point
inhibitor dose response as described previously and in Fig. S2 of the Supplementary Material. Curves were ﬁt to a sigmoidal doseeresponse (variable slope) equation using the
doseeresponse SMART protocol (http://www.promega.com/resources/tools/). The percentages of activity remaining for kinases are shown and represent the averages of two
replicates. (B) Proﬁling the SB203580 compound against the 112-kinase panel using the strip approach. Using the doseeresponse SMART protocol, IC50 values for kinases were
collected and converted in Microsoft Excel to different size bubbles to represent the potency of the compound against the kinases.
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[23]. A panel of 300 recombinant protein kinases was used with a
library of 178 compounds. Only 106 kinases from our panel were
proﬁled in the radiometric panel. Therefore, we compared theTable 3
IC50 values calculated for SB203580 toward the
kinases in the panel.
Kinasea IC50 (nM)
p38a 16
RIPK2 46
p38b 114
JNK3 466
ALK4 853
CK1ε 937
BRK 1334
TNIK 1382
GSK3b 1513
HER2 2081
CK1a1 3007
RET 3219
JNK1 3272
ALK2 4872
HER4 5053
FGFR1 7271
a For the rest of the kinases, no IC50 could be
calculated because the compound had no
detectable potency.data generated with our panel for six compounds with the data
generated using the radiometric assay for those 106 kinases. The
heat map comparison in Fig. 7 shows good correlation between
bioluminescent proﬁling strip data and the HotSpot data. Indeed,
more than 95% of the inhibition values fall within the same range
of activity. Because our assay was performed at 1 mM compound
concentration compared with 0.5 mM for the radiometric assay, a
few kinases show a slight shift in inhibition proﬁle either from
high activity remaining (blue) to medium activity (white) or from
medium activity remaining (white) to low activity (red). An
example of the latter is RIPK2, whose inhibition by three of the
small molecules tested was also conﬁrmed. The observed close
correlation to a radiometric kinase assay method reinforces the
validation of the proﬁling strips method to generate accurate
inhibitor proﬁles in an uncomplicated fashion. By using the
bioluminescent approach to generate proﬁling data, we elimi-
nated undesirable aspects associated with the use of radioactivity
or outsourcing.Simultaneous proﬁling of protein and lipid kinases
A desirable component of a simple proﬁling technique is an
assay that detects the activity of all the kinases simultaneously.
Lipid kinases have special requirements for assay development
due to the intricate nature of the lipid substrates. Therefore,
J. Hennek et al. / Analytical Biochemistry 495 (2016) 9e20 17speciﬁc assays are used to assess their activities, making them
difﬁcult to be included with protein kinases in one setup. This is
not an issue when using the luminescent ADP detection assay
given that it was previously validated for its robustness and ac-
curacy in detecting the activity of lipid kinases such as PI3 and PI4
kinases [47,51]. We applied our kinase standardizing approach to
lipid kinases and created a strip containing the PI3 kinases a, b, g,
and d. The PI3K strip was used along with the “Other/CK1” strip
containing protein kinases from the CK1, the “Other” kinome
branch, and DNA-PK. We analyzed the activity of four known PI3K
inhibitors: broad-spectrum PI3K inhibitor LY294002, speciﬁc
PI3Kb inhibitor AZD6482, and two PI3Kg inhibitors AS252424 and
AS605240. The inhibition proﬁles of these inhibitors are presented
in Fig. 8, and the IC50 values generated are shown in Table S2 of
the Supplementary Material. All four inhibitors are active with
different potencies and different IC50 ranges against all of the PI3
kinases. An exception is AS252424, which inhibits the target PI3Kg
with a low IC50 of 52 nM and the other PI3 kinases with high IC50
but does not inhibit PI3Kb (Fig. 8D). DNA-PK, which belongs to the
same “ATYPICAL” kinome branch as the PI3 kinases (Fig. 1), was
also inhibited, as was previously shown by AZD6482 and
LY294002 compounds [52]. We found that AS605240 showed the
highest potency against DNA-PK with an IC50 of 16.3 nM, which is
within the same range to its PI3Kg inhibition (6.4 nM) that this
compound is known to be selective for (Fig. 8C and Table S2). The
IC50 values obtained and the rank orders for these inhibitors are
also similar to those in previous reports [52e54]. Surprisingly, we
found that in the “Other/CK1” family the protein kinase CK2 was
inhibited by AS605240 and AS252424 with potencies similar to
that for PI3Kg (Fig. 8C and D). AS252424 was previously reported
to inhibit CK2 with no discussion from the authors of the report
about a potential effect on the CK2 pathway [54]. AS605240 was
not reported to inhibit CK2. Both compounds were reported to
speciﬁcally inhibit the PI3Kg pathway, leading to conclusions that
these compounds could have potential application in the treat-
ment of PI3K-mediated chronic inﬂammatory diseases such as
glomerulonephritis [55e57]. CK2 phosphorylates hundreds of
substrates and potentially participates in the regulation of diverse
cellular processes [58]. During recent years, this ubiquitous kinase
was also shown to be involved in inﬂammation [59,60]. Our
ﬁnding that CK2 is highly inhibited by these PI3Kg compounds
suggests that the effects observed on the regulation of inﬂam-
matory responses could be attributed to CK2 or could synergisti-
cally involve both the PI3Kg and CK2 pathways [55,60]. This
emphasizes the importance of including lipid and protein kinases
in proﬁling experiments to rule out any misinterpretations or
erroneous conclusions related to the effects of compounds at the
cellular level.
We have shown here that lipid kinases can also be assembled in
strip format to be used with protein kinases in the same proﬁling
experiments. Proﬁling these kinases in strips easily identiﬁes
compound selectivity towardmembers of the PI3 kinase family and
deﬁnes rank orders. Finally, because compounds were proﬁled
simultaneously against lipid and protein kinases, unknown off-Fig.7. Comparison of large selectivity proﬁles generated with the luminescent and
radiometric approaches. Right panel: A total of 106 kinases from the kinase strips panel
were tested in the luminescent method described here against six compounds known
for their speciﬁc inhibition proﬁles at 1 mM concentration. The single-dose inhibition
protocol and data collection were performed as described in Fig. 3. Percentages of
activity remaining for kinase/compound pairs are shown as a heat map representing
different kinase activity ranges. Left panel: Data produced by a radiometric assay [23]
for the same 106 kinases was collected from the publication and converted to a heat
map for comparison with the luminescent approach.
Fig.8. Selectivity proﬁling of PI3 kinase inhibitors. Lipid kinase inhibitors LY294002 (A), AZD 6482 (B), AS605240 (C), and AS252424 (D) were proﬁled against PI3 kinases and
selected protein kinases simultaneously using the strip approach. To have the 12 kinases together in one graph, curves were ﬁt to a sigmoidal doseeresponse (variable slope)
equation using GraphPad Prism software. The percentages of activity remaining for kinase/compound pairs are shown and represent the averages of two replicates. IC50 values
calculated are presented in Table S2 of the Supplementary Material.
J. Hennek et al. / Analytical Biochemistry 495 (2016) 9e2018target effects that would have been missed otherwise were
identiﬁed.
Conclusions
During drug development, proﬁling kinase inhibitors is a crucial
step that allows medicinal chemists to pursue lead compound
optimization and dial in a good balance between potency and
selectivity. Early and iterative availability of this information during
the optimization process supports the development of efﬁcacious
drugs with minimal side effects later in the clinic and lowers the
attrition rate of drug candidates. Many techniques are available to
assess the potency of an inhibitor on kinase activity. However, to
assess selectivity of a compound, there are many challenges that
can be encountered. First, to perform a proﬁling experiment, mul-
tiple kinases need to be assayed at the same time, and one kinase
assay method might not be suitable for all of them. This challenge
can be overcome with a generic assay that detects the activity of all
kinases regardless of the nature of their substrates. We accom-
plished this in the current examples with an assay that measures
production of the universal kinase product ADP. Second, assay
development for each kinase in the proﬁling panel and the main-
tenance of kinase enzyme stability and supply can be challenging.
We overcame this challenge by developing a simple biolumines-
cent proﬁling platform based on the functional ADP detection
assay. Our method relies on standardizing kinase activities and
creating pre-conﬁgured kinase stocks that are used in kinase re-
actions to create either inhibitor single-dose or doseeresponse
proﬁles. Our method provides a simple but powerful tool to
streamline the proﬁling process and routinely generate proﬁling
data in an uncomplicated manner. The data generated by this new
approach are comparable to previously reported methods without
the associated technical challenges such as heavy assaydevelopment, safety due to radioactive material management, and
inconveniences related to outsourcing. We showed that by using
the kinase proﬁling strip approach, we could easily generate
selectivity proﬁles with either small or large kinase panels. This
novel approach can be easily adopted by scientists such as medic-
inal chemists and chemical biologists for regular in-house kinase
inhibitor proﬁling.Acknowledgments
We thank Jim Cali for his critical reading of the manuscript,
Vincent Lee for helping with kinase strip assembly, Jun Yan for
kindly providing enzymes, Mark Bratz for creating the SMART
protocol data analysis tool, and Michael Stormberg for creating the
kinome dendogram image. The authors are former or current em-
ployees of Promega Corporation or Signalchem Pharmaceuticals.Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.ab.2015.11.007.References
[1] G. Manning, D.B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, The protein
kinase complement of the human genome, Science 298 (2002) 1912e1934.
[2] P.V. Hornbeck, J.M. Kornhauser, S. Tkachev, B. Zhang, E. Skrzypek, B. Murray,
V. Latham, M. Sullivan, PhosphoSitePlus: a comprehensive resource for
investigating the structure and function of experimentally determined post-
translational modiﬁcations in man and mouse, Nucleic Acids Res. 40 (2012)
D261eD270.
[3] T. Hunter, Signalingd2000 and beyond, Cell 100 (2000) 113e127.
[4] P. Cohen, Protein kinaseseethe major drug targets of the twenty-ﬁrst cen-
tury? Nat. Rev. Drug Discov. 1 (2002) 309e315.
J. Hennek et al. / Analytical Biochemistry 495 (2016) 9e20 19[5] P. Cohen, D.R. Alessi, Kinase drug discovery: what's next in the ﬁeld? ACS
Chem. Biol. 8 (2013) 96e104.
[6] P. Wu, T.E. Nielsen, M.H. Clausen, FDA-approved small-molecule kinase in-
hibitors, Trends Pharmacol. Sci. 36 (2015) 422e439.
[7] M.H. Cohen, G. Williams, J.R. Johnson, J. Duan, J. Gobburu, A. Rahman,
K. Benson, J. Leighton, S.K. Kim, R. Wood, M. Rothmann, G. Chen, K. Maung-U,
A.M. Staten, R. Pazdur, Approval summary for imatinib mesylate capsules in
the treatment of chronic myelogenous leukemia, Clin. Cancer Res. 8 (2002)
935e942.
[8] A. Ganetsky, Ruxolitinib: a new treatment option for myeloﬁbrosis, Pharma-
cotherapy 33 (2013) 84e92.
[9] E.B. Lee, R. Fleischmann, S. Hall, B. Wilkinson, J.D. Bradley, D. Gruben, T. Koncz,
S. Krishnaswami, G.V. Wallenstein, C. Zang, S.H. Zwillich, R.F. van Vollenhoven,
Tofacitinib versus methotrexate in rheumatoid arthritis, N. Engl. J. Med. 370
(2014) 2377e2386.
[10] L. Richeldi, R.M. du Bois, G. Raghu, A. Azuma, K.K. Brown, U. Costabel, V. Cottin,
K.R. Flaherty, D.M. Hansell, Y. Inoue, D.S. Kim, M. Kolb, A.G. Nicholson,
P.W. Noble, M. Selman, H. Taniguchi, M. Brun, F. Le Maulf, M. Girard,
S. Stowasser, R. Schlenker-Herceg, B. Disse, H.R. Collard, Efﬁcacy and safety of
nintedanib in idiopathic pulmonary ﬁbrosis, N. Engl. J. Med. 370 (2014)
2071e2082.
[11] C. Widakowich, G. de Castro, E. de Azambuja, P. Dinh, A. Awada, Review: Side
effects of approved molecular targeted therapies in solid cancers, Oncologist
12 (2007) 1443e1455.
[12] P.J. Barnes, New anti-inﬂammatory targets for chronic obstructive pulmonary
disease, Nat. Rev. Drug Discov. 12 (2013) 543e559.
[13] M. Rask-Andersen, J. Zhang, D. Fabbro, H.B. Schi€oth, Advances in kinase tar-
geting: current clinical use and clinical trials, Trends Pharmacol. Sci. 35 (2014)
604e620.
[14] R.E. Castoldi, G. Pennella, G.S. Saturno, P. Grossi, M. Brughera, M. Venturi,
Assessing and managing toxicities induced by kinase inhibitors, Curr. Opin.
Drug Discov. Dev. 10 (2007) 53e57.
[15] A.J. Olaharski, N. Gonzaludo, H. Bitter, D. Goldstein, S. Kirchner, H. Uppal,
K. Kolaja, Identiﬁcation of a kinase proﬁle that predicts chromosome damage
induced by small molecule kinase inhibitors, PLoS Comput. Biol. 5 (7) (2009)
e1000446.
[16] J. Bain, L. Plater, M. Elliott, N. Shpiro, C.J. Hastie, H. Mclauchlan, I. Klevernic,
J. Simon, C. Arthur, D.R. Alessi, P. Cohen, The selectivity of protein kinase in-
hibitors: a further update, Biochem. J. 408 (2007) 297e315.
[17] Y. Hu, N. Furtmann, J. Bajorath, Current compound coverage of the kinome,
J. Med. Chem. 58 (2015) 30e40.
[18] Y. Jia, C.M. Quinn, S. Kwak, R.V. Talanian, Current in vitro kinase assay tech-
nologies: the quest for a universal format, Curr. Drug Discov. Technol. 5 (2008)
59e69.
[19] H. Zegzouti, M. Zdanovskaia, K. Hsiao, S.A. Goueli, ADP-Glo: a bioluminescent
and homogeneous ADP monitoring assay for kinases, assay, Drug Dev. Tech-
nol. 7 (2009) 560e572.
[20] R. Krishnamurty, D.J. Maly, Chemical genomic and proteomic methods for
determining kinase inhibitor selectivity, Comb. Chem. High. Throughput
Screen 10 (2007) 652e666.
[21] Y. Luo, Selectivity assessment of kinase inhibitors: strategies and challenges,
Curr. Opin. Mol. Ther. 7 (2005) 251e255.
[22] C.V. Miduturu, X. Deng, N. Kwiatkowski, W. Yang, L. Brault, P. Filippakopoulos,
E. Chung, Q. Yang, J. Schwaller, S. Knapp, R.W. King, J.-D. Lee, S. Herrgard,
P. Zarrinkar, N.S. Gray, High-throughput kinase proﬁling: a more efﬁcient
approach towards the discovery of new kinase inhibitors, Chem. Biol. 18
(2011) 868e879.
[23] T. Anastassiadis, S.W. Deacon, K. Devarajan, H. Ma, J.R. Peterson, Compre-
hensive assay of kinase catalytic activity reveals features of kinase inhibitor
selectivity, Nat. Biotechnol. 29 (2011) 1039e1045.
[24] M.A. Fabian, W.H. Biggs, D.K. Treiber, C.E. Atteridge, M.D. Azimioara,
M.G. Benedetti, T.A. Carter, P. Ciceri, P.T. Edeen, M. Floyd, J.M. Ford, M. Galvin,
J.L. Gerlach, R.M. Grotzfeld, S. Herrgard, D.E. Insko, M.A. Insko, A.G. Lai, J.-
M. Lelias, S.A. Mehta, Z.V. Milanov, A.M. Velasco, L.M. Wodicka, H.K. Patel,
P.P. Zarrinkar, D.J. Lockhart, A small moleculeekinase interaction map for
clinical kinase inhibitors, Nat. Biotechnol. 23 (2005) 329e336.
[25] M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge,
B.T. Campbell, K.W. Chan, P. Ciceri, M.I. Davis, P.T. Edeen, R. Faraoni, M. Floyd,
J.P. Hunt, D.J. Lockhart, Z.V. Milanov, M.J. Morrison, G. Pallares, H.K. Patel,
S. Pritchard, L.M. Wodicka, P.P. Zarrinkar, A quantitative analysis of kinase
inhibitor selectivity, Nat. Biotechnol. 26 (2008) 127e132.
[26] Y. Gao, S.P. Davies, M. Augustin, A. Woodward, U.A. Patel, R. Kovelman,
K.J. Harvey, A broad activity screen in support of a chemogenomic map for
kinase signalling research and drug discovery, Biochem. J. 451 (2013)
313e328.
[27] D. Kitagawa, K. Yokota, M. Gouda, Y. Narumi, H. Ohmoto, E. Nishiwaki,
K. Akita, Y. Kirii, Activity-based kinase proﬁling of approved tyrosine kinase
inhibitors, Genes Cells 18 (2013) 110e122.
[28] A. Card, C. Caldwell, H. Min, B. Lokchander, H. Xi, S. Sciabola, A.V. Kamath,
S.L. Clugston, W.R. Tschantz, L. Wang, D.J. Moshinsky, High-throughput
biochemical kinase selectivity assays: panel development and screening ap-
plications, J. Biomol. Screen 14 (2009) 31e42.
[29] B. Larson, P. Banks, H. Zegzouti, S.A. Goueli, A simple and robust automated
kinase proﬁling platform using luminescent ADP accumulation technology,
assay, Drug Dev. Technol. 7 (2009) 573e584.[30] H. Zegzouti, J. Alves, T. Worzella, G. Vidugiris, G. Cameron, J. Vidugiriene,
S. Goueli, Screening and Proﬁling Kinase Inhibitors With a Luminescent ADP
Detection Platform, Promega, 2011. Available from: http://www.promega.
com/resources/pubhub/screening-and-proﬁling-kinase-inhibitors-with-a-
luminescent-adp-detection-platform/.
[31] C. Tanega, M. Shen, B.T. Mott, C.J. Thomas, R. MacArthur, J. Inglese, D.S. Auld,
Comparison of bioluminescent kinase assays using substrate depletion and
product formation, assay, Drug Dev. Technol. 7 (2009) 606e614.
[32] S.B. Berger, P. Harris, R. Nagilla, V. Kasparcova, S. Hoffman, B. Swift, L. Dare,
M. Schaeffer, C. Capriotti, M. Ouellette, B.W. King, D. Wisnoski, J. Cox, M. Reilly,
R.W. Marquis, J. Bertin, P.J. Gough, Characterization of GSK'963: a structurally
distinct, potent, and selective inhibitor of RIP1 kinase, Cell Death Discov. 1
(2015) 15009, http://dx.doi.org/10.1038/cddiscovery.2015.9.
[33] C. Antczak, A. Bermingham, P. Calder, D. Malkov, K. Song, J. Fetter,
H. Djaballah, Domain-based biosensor assay to screen for epidermal growth
factor receptor modulators in live cells, assay, Drug Dev. Technol. 10 (2012)
24e36.
[34] S.K.C. Basnet, S. Diab, R. Schmid, M. Yu, Y. Yang, T.A. Gillam, T. Teo, P. Li,
T. Peat, H. Albrecht, S. Wang, Identiﬁcation of a highly conserved allosteric
binding site on Mnk1 and Mnk2, Mol. Pharmacol. 88 (2015) 935e948.
[35] T. Luo, K. Masson, J.D. Jaffe, W. Silkworth, N.T. Ross, C.A. Scherer, C. Scholl,
S. Fr€ohling, S.A. Carr, A.M. Stern, S.L. Schreiber, T.R. Golub, STK33 kinase in-
hibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability, Proc.
Natl. Acad. Sci. U. S. A. 109 (2012) 2860e2865.
[36] S. Santaguida, C. Vernieri, F. Villa, A. Ciliberto, A. Musacchio, Evidence that
Aurora B is implicated in spindle checkpoint signalling independently of error
correction, EMBO J. 30 (2011) 1508e1519.
[37] H. Zegzouti, J. Hennek, S. Goueli, Using bioluminescent kinase proﬁling strips
to identify inhibitor selectivity and promiscuity, Methods Mol. Biol. 1360
(2016) 59e73.
[38] D.K. Heidary, G. Huang, D. Boucher, J. Ma, C. Forster, R. Grey, J. Xu, M. Arnost,
D. Choquette, G. Chen, J.-H. Zhou, Y.-M. Yao, E.D. Ball, M. Namchuk, R.J. Davies,
G. Henkel, VX-322: a novel dual receptor tyrosine kinase inhibitor for the
treatment of acute myelogenous leukemia, J. Med. Chem. 55 (2012) 725e734.
[39] C-H. Yun, T.J. Boggon, Y. Li, M.S. Woo, H. Greulich, M. Meyerson, M.J. Eck,
Structures of lung cancer-derived EGFR mutants and inhibitor complexes:
mechanism of activation and insights into differential inhibitor sensitivity,
Cancer Cell 11 (2007) 217e227.
[40] M. Steinberg, Dasatinib: a tyrosine kinase inhibitor for the treatment of
chronic myelogenous leukemia and philadelphia chromosome-positive acute
lymphoblastic leukemia, Clin. Ther. 29 (2007) 2289e2308.
[41] S. Bach, M. Knockaert, J. Reinhardt, O. Lozach, S. Schmitt, B. Baratte, M. Koken,
S.P. Coburn, L. Tang, T. Jiang, D.-C. Liang, H. Galons, J.-F. Dierick, L.A. Pinna,
F. Meggio, F. Totzke, C. Sch€achtele, A.S. Lerman, A. Carnero, Y. Wan, N. Gray,
L. Meijer, Roscovitine targets, protein kinases, and pyridoxal kinase, J. Biol.
Chem. 280 (2005) 31208e31219.
[42] A. Cuenda, J. Rouse, Y.N. Doza, R. Meier, P. Cohen, T.F. Gallagher, P.R. Young,
J.C. Lee, SB 203580 is a speciﬁc inhibitor of a MAP kinase homologue which is
stimulated by cellular stresses and interleukin-1, FEBS Lett. 364 (1995)
229e233.
[43] S. Kumar, M.S. Jiang, J.L. Adams, J.C. Lee, Pyridinylimidazole compound SB
203580 inhibits the activity but not the activation of p38 mitogen-activated
protein kinase, Biochem. Biophys. Res. Commun. 263 (1999) 825e831.
[44] J.D. Parsons, A high-throughput method for ﬁtting doseeresponse curves
using Microsoft Excel, Anal. Biochem. 360 (2007) 309e311.
[45] J.T. Tigno-Aranjuez, P. Benderitter, F. Rombouts, F. Deroose, X. Bai, B. Mattioli,
F. Cominelli, T.T. Pizarro, J. Hoﬂack, D.W. Abbott, In vivo inhibition of RIPK2
kinase alleviates inﬂammatory disease, J. Biol. Chem. 289 (2014)
29651e29664.
[46] H. Ma, S. Deacon, K. Horiuchi, The challenge of selecting protein kinase assays
for lead discovery optimization, Expert Opin. Drug Discov. 3 (2008) 607e621.
[47] A.W. Tai, N. Bojjireddy, T. Balla, A homogeneous and nonisotopic assay for
phosphatidylinositol 4-kinases, Anal. Biochem. 417 (2011) 97e102.
[48] M.I. Davis, J.P. Hunt, S. Herrgard, P. Ciceri, L.M. Wodicka, G. Pallares,
M. Hocker, D.K. Treiber, P.P. Zarrinkar, Comprehensive analysis of kinase in-
hibitor selectivity, Nat. Biotechnol. 29 (2011) 1046e1051.
[49] G. Medard, F. Pachl, B. Ruprecht, S. Klaeger, S. Heinzlmeir, D. Helm, H. Qiao,
X. Ku, M. Wilhelm, T. Kuehne, Z. Wu, A. Dittmann, C. Hopf, K. Kramer,
B. Kuster, Optimized chemical proteomics assay for kinase inhibitor proﬁling,
J. Proteome Res. 14 (2015) 1574e1586.
[50] M.P. Patricelli, T.K. Nomanbhoy, J. Wu, H. Brown, D. Zhou, J. Zhang,
S. Jagannathan, A. Aban, E. Okerberg, C. Herring, B. Nordin, H. Weissig, Q. Yang,
J.-D. Lee, N.S. Gray, J.W. Kozarich, In situ kinase proﬁling reveals functionally
relevant properties of native kinases, Chem. Biol. 18 (2011) 699e710.
[51] A.W. Tai, J. Vidugiriene, Measuring activity of phosphoinositide lipid kinases
using a bioluminescent ADP-detecting assay, Methods Mol. Biol. 1360 (2016)
75e85.
[52] Z.A. Knight, B. Gonzalez, M.E. Feldman, E.R. Zunder, D.D. Goldenberg,
O. Williams, R. Loewith, D. Stokoe, A. Balla, B. Toth, T. Balla, W.A. Weiss,
R.L. Williams, K.M. Shokat, A pharmacological map of the PI3-K family deﬁnes
a role for p110a in insulin signaling, Cell 125 (2006) 733e747.
[53] D. Kong, T. Yamori, Phosphatidylinositol 3-kinase inhibitors: promising drug
candidates for cancer therapy, Cancer Sci. 99 (2008) 1734e1740.
[54] V. Pomel, J. Klicic, D. Covini, D.D. Church, J.P. Shaw, K. Roulin, F. Burgat-
Charvillon, D. Valognes, M. Camps, C. Chabert, C. Gillieron, B. Françon,
J. Hennek et al. / Analytical Biochemistry 495 (2016) 9e2020D. Perrin, D. Leroy, D. Gretener, A. Nichols, P.A. Vitte, S. Carboni, C. Rommel,
M.K. Schwarz, T. Rückle, Furan-2-ylmethylene thiazolidinediones as novel,
potent, and selective inhibitors of phosphoinositide 3-kinase g, J. Med. Chem.
49 (2006) 3857e3871.
[55] D.F. Barber, A. Bartolome, C. Hernandez, J.M. Flores, C. Redondo, C. Fernandez-
Arias, M. Camps, T. Ruckle, M.K. Schwarz, S. Rodriguez, C. Martinez-A,
D. Balomenos, C. Rommel, A.C. Carrera, PI3Kg inhibition blocks glomerulo-
nephritis and extends lifespan in a mouse model of systemic lupus, Nat. Med.
11 (2005) 933e935.
[56] M. Camps, T. Ruckle, H. Ji, V. Ardissone, F. Rintelen, J. Shaw, C. Ferrandi,
C. Chabert, C. Gillieron, B. Francon, T. Martin, D. Gretener, D. Perrin, D. Leroy,
P.-A. Vitte, E. Hirsch, M.P. Wymann, R. Cirillo, M.K. Schwarz, C. Rommel,
Blockade of PI3Kg suppresses joint inﬂammation and damage in mouse
models of rheumatoid arthritis, Nat. Med. 11 (2005) 936e943.[57] M. Jin, Q. Zhou, E. Lee, S. Dan, H.Q. Duan, D. Kong, AS252424, a PI3Kg inhibitor,
downregulates inﬂammatory responsiveness in mouse bone marrow-derived
mast cells, Inﬂammation 37 (2014) 1254e1260.
[58] D.W. Litchﬁeld, Protein kinase CK2: structure, regulation, and role in cellular
decisions of life and death, Biochem. J. 369 (2003) 1e15.
[59] N.N. Singh, D.P. Ramji, Protein kinase CK2, an important regulator of the in-
ﬂammatory response? J. Mol. Med. 86 (2008) 887e897.
[60] M. Yamada, S. Katsuma, T. Adachi, A. Hirasawa, S. Shiojima, T. Kadowaki,
Y. Okuno, T.-A. Koshimizu, S. Fujii, Y. Sekiya, Y. Miyamoto, M. Tamura,
W. Yumura, H. Nihei, M. Kobayashi, G. Tsujimoto, Inhibition of protein kinase
CK2 prevents the progression of glomerulonephritis, Proc. Natl. Acad. Sci. U. S.
A. 102 (2005) 7736e7741.
